AB Or Not AB? Barr & Sandoz Ponder The Biogeneric Substitution Question

Generic manufacturers may not want substitutability for follow-on biologics, Barr CEO Bruce Downey said Sept. 19 at the Generic Pharmaceutical Association Annual Policy Conference in Washington, D.C